UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December 31, 2018
ARATANA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
001-35952 |
38-3826477 |
||
|
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
11400 Tomahawk Creek Parkway, Suite 340, Leawood, KS 66211
(Address of principal executive offices) (Zip Code)
(913) 353-1000
(Registrant’s telephone number, include area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective as of the conclusion of the day on December 31, 2018, Brent Standridge retired from Aratana Therapeutics, Inc. (the “Company”) as Chief Operating Officer of the Company pursuant to Section 4.5.2 of his employment agreement, which was filed with the Securities and Exchange Commission as Exhibit 10.1 to the Company’s Current Report on Form 8-K on June 30, 2016. Mr. Standridge has agreed to remain with the Company as a consultant during which he will perform a variety of duties for the Company, including assisting with the transition of his various responsibilities within the Company’s commercial organization.
.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ARATANA THERAPEUTICS, INC. |
||||||
|
Date: January 4, 2019 |
By: |
|||||
|
/s/ Steven St. Peter |
||||||
|
Steven St. Peter |
||||||
|
President and Chief Executive Officer |
||||||